Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Predilatation in Self-Expanding Valves

TAVI has become the treatment of choice in specific scenarios. However, predilatation (PRD) remains a matter of debate, both in balloon-expandable and self-expanding valves.

Currently, there are analyses in which PRD was performed or even considered mandatory, and others where it was not carried out, yielding controversial results regarding this strategy.

An analysis of the BAVSE-TAVI Registry (Balloon Aortic Valvuloplasty before Self-Expanding TAVI) was conducted, including 315 consecutive patients with symptomatic severe aortic stenosis treated with TAVI, of whom 158 underwent PRD.

The valves used were Evolut PRO, PRO+, and FX (Medtronic, Minneapolis, MN).

The Primary Endpoint (PE) was a composite of all-cause death, stroke, major vascular complications, major bleeding, significant paravalvular leak, or the need for a permanent pacemaker.

Read also: Flow Protocols in VA-ECMO: Impact on PCWP in Cardiogenic Shock.

Baseline characteristics were similar between groups: mean age of 81 years, EuroSCORE of 3.6%, renal dysfunction in 50%, atrial fibrillation in 23%, right bundle branch block in 6%, and left bundle branch block in 4%. Pacemaker implantation was more frequent in patients undergoing direct implantation (DI).

Patients who received PRD had higher peak velocity (4.5 vs. 4 m/s; p<0.001), smaller indexed aortic valve area (0.3 vs. 0.4; p<0.001), larger annulus area (446 vs. 408 mm²; p<0.001 and 76 vs. 73 mm²; p=0.012), and higher peak and mean gradients (84 vs. 69 mmHg; p<0.001 and 51 vs. 40 mmHg; p<0.001). They also presented with higher calcification scores and more bicuspid valves.

No differences were observed in valve diameters; however, post-dilatation was more frequent in patients who had undergone PRD.

Read also: Tricuspid Regurgitation, TriBicaval Registry.

There were no significant differences in the PE, nor in death, stroke, vascular complications, paravalvular leak, or permanent pacemaker requirement. However, major bleeding was more frequent in the DI group (0.6% vs. 6.4%; p=0.005).

At two-year follow-up, no differences in mortality were observed (23.4% vs. 31.2%; p=0.131 for PRD and DI, respectively).

Conclusion

Both predilatation and direct implantation in TAVI can be safely performed in clinical practice. The choice of strategy should be based on patient characteristics assessed by echocardiography and computed tomography.

Original Title: Balloon Aortic Valvuloplasty Prior to Self‐Expanding TAVI: The BAVSE‐TAVI Registry. 

Reference: Abdalazeem Ibrahem, et a. Catheterization and Cardiovascular Interventions, 2025; 106:1674–1681.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...